These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 38473726)
1. P53 and Rb Aberrations in Small Cell Lung Cancer (SCLC): From Molecular Mechanisms to Therapeutic Modulation. Papavassiliou KA; Sofianidi AA; Gogou VA; Anagnostopoulos N; Papavassiliou AG Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473726 [TBL] [Abstract][Full Text] [Related]
2. Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset. Febres-Aldana CA; Chang JC; Ptashkin R; Wang Y; Gedvilaite E; Baine MK; Travis WD; Ventura K; Bodd F; Yu HA; Quintanal-Villalonga A; Lai WV; Egger JV; Offin M; Ladanyi M; Rudin CM; Rekhtman N Clin Cancer Res; 2022 Nov; 28(21):4702-4713. PubMed ID: 35792876 [TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer. Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033 [TBL] [Abstract][Full Text] [Related]
4. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530 [TBL] [Abstract][Full Text] [Related]
5. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622 [TBL] [Abstract][Full Text] [Related]
6. Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer. Hao L; Chen H; Wang L; Zhou H; Zhang Z; Han J; Hou J; Zhu Y; Zhang H; Wang Q Thorac Cancer; 2023 Apr; 14(11):1036-1041. PubMed ID: 36810856 [TBL] [Abstract][Full Text] [Related]
7. Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer. Wildey G; Shay AM; McColl KS; Yoon S; Shatat MA; Perwez A; Spainhower KB; Kresak AM; Lipka M; Yang M; Behtaj M; Fu P; Alahmadi A; Mneimneh W; Abbas A; Dowlati A Mol Cancer Ther; 2023 Feb; 22(2):264-273. PubMed ID: 36399634 [TBL] [Abstract][Full Text] [Related]
8. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers. Li J; Wei B; Feng J; Wu X; Chang Y; Wang Y; Yang X; Zhang H; Han S; Zhang C; Zheng J; Groen HJM; van den Berg A; Ma J; Li H; Guo Y Front Endocrinol (Lausanne); 2022; 13():1006480. PubMed ID: 36583000 [TBL] [Abstract][Full Text] [Related]
9. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Schaffer BE; Park KS; Yiu G; Conklin JF; Lin C; Burkhart DL; Karnezis AN; Sweet-Cordero EA; Sage J Cancer Res; 2010 May; 70(10):3877-83. PubMed ID: 20406986 [TBL] [Abstract][Full Text] [Related]
10. Small cell lung cancer: significance of RB alterations and TTF-1 expression in its carcinogenesis, phenotype, and biology. Kitamura H; Yazawa T; Sato H; Okudela K; Shimoyamada H Endocr Pathol; 2009; 20(2):101-7. PubMed ID: 19390995 [TBL] [Abstract][Full Text] [Related]
11. Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epithelium. Chen J; Guanizo A; Luong Q; Jayasekara WSN; Jayasinghe D; Inampudi C; Szczepny A; Garama DJ; Russell PA; Ganju V; Cain JE; Watkins DN; Gough DJ Oncogene; 2022 Jan; 41(1):138-145. PubMed ID: 34675406 [TBL] [Abstract][Full Text] [Related]
12. Characterization of the cell of origin for small cell lung cancer. Park KS; Liang MC; Raiser DM; Zamponi R; Roach RR; Curtis SJ; Walton Z; Schaffer BE; Roake CM; Zmoos AF; Kriegel C; Wong KK; Sage J; Kim CF Cell Cycle; 2011 Aug; 10(16):2806-15. PubMed ID: 21822053 [TBL] [Abstract][Full Text] [Related]
13. Targeted pharmacologic inhibition of S-phase kinase-associated protein 2 (SKP2) mediated cell cycle regulation in lung and other RB-Related cancers: A brief review of current status and future prospects. Elahi AH; Morales CS; Xu XL; Eliades A; Patsalis PC; Abramson DH; Jhanwar SC Adv Biol Regul; 2023 May; 88():100964. PubMed ID: 37004354 [TBL] [Abstract][Full Text] [Related]
14. Targeted Inhibition of the E3 Ligase SCF Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224 [TBL] [Abstract][Full Text] [Related]